Loading clinical trials...
Loading clinical trials...
Evaluation of the efficacy and safety of Mecapegfilgrastim for the prevention of neutropenia and radiation esophagitis after hyperfractionation in patients with limited-stage small cell lung cancer
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
NCT07177937 · Small Cell Lung Cancer, Melanoma, and more
NCT05671510 · Non Small Cell Lung Cancer
NCT06043817 · Non-Small Cell Lung Cancer, NSCLC, and more
NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more
NCT06646276 · Extensive-Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions